Objective: To examine the association between 6-min walk test (6 MWT) performance and all-cause mortality, coronary heart disease mortality, and incident coronary heart disease in older adults. Method: We conducted a time-to-event analysis of 1,665 Cardiovascular Health Study participants of Aging and HealthYazdanyar et al.
Introduction
Exercise capacity has been shown to predict cardiovascular events and allcause mortality in adult populations (Blair et al., 1996; Goraya et al., 2000; Gulati et al., 2003; Kokkinos et al., 2008; Messinger-Rapport, Pothier Snader, Blackstone, Yu, & Lauer, 2003; Mora et al., 2003; Myers et al., 2002; Spin et al., 2002; Sui, Laditka, Hardin, & Blair, 2007) . Treadmill-based and walkbased testing represents alternate methods for the assessment of functional exercise capacity (Fleg et al., 2000) . While exercise treadmill testing has been the most commonly applied method, older adults encounter greater limitations in their ability to execute a treadmill-based test (Gill, DiPietro, & Krumholz, 2000) . A walk-based method may serve as a better reflection of daily activities and more practical for assessing functional capacity in older adults (Greig, Butler, Skelton, Mahmud, & Young, 1993; Hollenberg, Ngo, Turner, & Tager, 1998; Peeters & Mets, 1996) .
The 6-min walk test (MWT) is a simple, safe, and easily administered test, which has been studied in various disease-specific populations, including individuals with pulmonary disease, heart failure, pacemakers, peripheral arterial disease, and organ transplant candidates (Bernstein et al., 1994; Bittner et al., 1993; L. Cahalin, Pappagianopoulos, Prevost, Wain, & Ginns, 1995; L. P. Cahalin, Mathier, Semigran, Dec, & DiSalvo, 1996; Langenfeld et al., 1990; Milligan, Havey, & Dossa, 1997; Montgomery & Gardner, 1998; Wijkstra et al., 1994) . Among older adults, the 6 MWT has been shown to be a reliable and valid measure of functional capacity (Rikli & Jones, 1998) .
While the 6 MWT performance has been shown to be of prognostic significance in various disease-specific patient populations, the information on the association between the 6 MWT and health outcomes among communitydwelling older adults is limited. We investigated the association between the 6 MWT performance and all-cause mortality, coronary heart disease-specific mortality, and incident coronary heart disease among community-dwelling older adults.
Method

Population
Cardiovascular Health Study (CHS) is an observational study with the primary goal of determining the risk factors for and consequences of cardiovascular disease in older adults. The design and methods of CHS have been previously described (Fried et al., 1991; Tell et al., 1993) . Briefly, 5,888 community-dwelling older adults were recruited, including an original cohort of 5,201 participants recruited in [1989] [1990] and an additional 687 predominantly African American cohort recruited between years 1992 and 1993. Recruitment was from a random sample of the Health Care Finance Administration Medicare eligibility lists in four U.S. communities: Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh (Allegheny County), Pennsylvania. Annual clinic visits and semi-annual telephone and clinic contacts included risk factors, measures of subclinical cardiovascular disease, cognitive and physical function. Of the 4,708 participants who remained enrolled in CHS between June 1996 and May 1997, 1,377 had a phone or proxy interview and did not have an in-person study visit. Among the 3,331 with an in-person study visit, 2,116 participants completed, 163 partially completed, and 1,052 were either excluded due to the criteria listed below (n = 764) or did not attempt the 6 MWT by either refusing testing (n = 39), stating physical inability (n = 34), lacking sufficient time (n = 2), at technician discretion (n = 28), or providing other reasons (n = 30), while the remaining did not participate in the 6 MWT for unknown reason (n = 155). Exclusion of participants with prevalent cardiovascular disease (n = 614) from the 2,279 who had either completed or partially completed the 6 MWT resulted in a final sample of 1,665 participants in the current analysis.
MWT
The 6 MWT was conducted between June 1996 and May 1997 according to a standard protocol (American Thoracic Society, 2002) . Briefly, in a 100 foot section of an internal hallway with distance marked every 5 feet by colored tape along the baseboard, participants were instructed to walk at their own pace up and down the hallway, while attempting to cover as much ground as possible. Technicians encouraged the participants with the standardized statements. Participants were allowed to stop and rest during the test, but were instructed to resume walking as soon as they could. If a participant stopped and refused to continue the test before the 6 minutes had elapsed, the distance walked was recorded and the walk was coded as a partial test. The technician used a mechanical lap counter to count the number of laps completed and an electronic timer with a buzzer that sounded the completion of the 6 minutes. Due to safety concerns, participants were excluded from the 6 MWT due to the presence of acute cardiac condition on the pre-test electrocardiogram (ECG), use of ambulatory aids, presence of severe aortic stenosis (<50 mm Hg gradient on echocardiogram), heart rate less than 50 beats per minute or greater than 110 beats per minute, systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg, or a myocardial infarction or revascularization in the previous 3 months, new or worsening chest pain, dyspnea, or fainting in the past 8 weeks, a resting oxygen saturation less than 90%, or at the discretion of the technician.
Potential Confounders
The CHS examinations were extensive, including risk factors and potential confounding or mediating variables of age, sex, race, cigarette smoking status (current vs. former or never), education level (less than high school vs. more than high school), history of treated hypertension or diabetes, body mass index (kg/m 2 ), systolic blood pressure (mm Hg), C-reactive protein (mg/dL), total cholesterol (mg/dL), and fasting glucose (mg/dL). Cognitive function was assessed using the Mini-Mental Status Exam (Folstein, Folstein, & McHugh, 1975) and depressive symptoms using the Center for Epidemiological Studies Depression (CES-D) score (Orme, Reis, & Herz, 1986) . Limitations in the Activities of Daily Living (ADL) or Instrumental Activities of Daily Living (IADL), self-reported general health status (fair or poor vs. good, very good, or excellent health) were assessed. Major ECG abnormalities including ventricular conduction defects, major Q or QS abnormalities, minor Q or QS with ST-T-wave abnormalities, left ventricular hypertrophy, isolated major ST-T-wave abnormalities, atrial fibrillation, or first degree atrioventricular block were determined by a centralized ECG Reading Center according to a standard protocol (Blackburn, 1969) . The ankle arm index (AAI) was measured by trained technicians according to a standard protocol . Chronic pulmonary disease was defined as a history of chronic bronchitis, emphysema, or asthma. Arthritis of the knees or hips was assessed by self-report. At study entry, participants were classified as having prevalent cardiovascular disease if they had a clinical history of coronary heart disease, congestive heart failure, stroke, transient ischemic attack, and peripheral artery disease, which were ascertained using methods previously described (Psaty et al., 1995) . Coronary heart disease was defined as the presence of myocardial infarction, angina, coronary artery bypass grafting, or angioplasty. Prevalent coronary heart and cardiovascular diseases were defined as those present at the time of 6 MWT from 1996 to 1997.
Outcomes
The method used by CHS for surveillance and ascertainment of mortality and cardiovascular events has been published elsewhere (Ives et al., 1995) . An incident coronary heart disease was defined as a myocardial infarction, angina, or coronary revascularization event among participants free of prevalent coronary heart disease at time of the 6 MWT. Incident cardiovascular disease was defined as incident coronary heart disease, congestive heart failure, stroke, or any atherosclerotic event. Mortality was documented by death certificates, inpatient records, nursing home or hospice records, physician questionnaires, and autopsy reports. A coronary heart disease-specific mortality was defined to include death from coronary heart disease and sudden death. Deaths and cardiovascular events were adjudicated by a CHS committee using a standardized protocol.
Statistical Analysis
Differences in covariates were tested using Analysis of Variance, Kruskal Wallis, or chi-square tests. The 6 MWT distance was categorized into quintiles of >414 m, 373 to 414 m, 338 to 373 m, 290 to 338 m, and 0 to 290 m. The longest distance quintile (>414 m) served as the referent group. Crude event rates were calculated and reported per 1,000 person-years. Cox proportional hazard regression was used to estimate hazard ratios (HRs) and event rates (per 1,000 person-years). Kaplan-Meier analysis was used to evaluate differences in study endpoints between the 6 MWT distance quintiles. Multivariable models included controls for age and sex, and subsequently for other covariates. To evaluate discrimination and improvement imparted by 6 MWT, we compared the adjusted model without 6 MWT (Model A) to adjusted model with the 6 MWT (Model B). Discrimination, the ability of two models to distinguish participants who develop a study endpoint from those who do not, was evaluated by Harrell's C statistic. We calculated category-free Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) to evaluate the improvement imparted by the addition of 6 MWT to Model A. All reported p values are based on a twosided test, with p value < .05 being considered statistically significant. Statistical analysis was performed using STATA MP 11.1 (StataCorp, College Station, Texas).
Results
There were 1,665 participants without prevalent cardiovascular disease among the 2,279 who attempted a 6 MWT with a mean age of 77 years. The participants were predominantly women (65%) and less likely to be of non-White race (15%). The mean 6 MWT distance was 349 m. As displayed in Table 1 , participants with longer 6 MWT distance performance had a more favorable characteristic profile such as younger age, lower body mass index, less likely to have limitations in IADL and ADLs, or to have arthritis of knees or hips.
MWT Distance and Mortality
There were 504 deaths among the 1,665 of the 2,279 participants without prevalent cardiovascular disease who attempted a 6 MWT (Table 2) . Figure  1shows the all-cause mortality Kaplan-Meier Survival curve by 6 MWT distance quintiles. Among the participants with a 6 MWT, a distance in the two shortest distance quintiles (walk distance 290-338 m and <290 m) was associated with an increased risk of all-cause mortality relative to a 6 MWT distance >414 m. The increased risk of all-cause mortality remained in age and sex-adjusted models. In a fully adjusted model, a 6 MWT distance in the shortest two performance quintiles remained associated with an increased risk of all-cause mortality. The adjusted risk of all-cause mortality was progressively higher with decreasing 6 MWT distance. Age-and sex-stratified analyses revealed a similar inverse association between 6 MWT performance and all-cause mortality (Table 3 ). Both older aged men and women who walked less than 338 m were at increased risk of all-cause mortality. The association between 6 MWT distance and mortality differed between White and non-White participants, with a significant association only observed among the White participants. Due to the small sample size of non-White participants with a 6 MWT, the lack of association among non-White participants should be interpreted with caution. Table 4 displays results of the tests of discrimination and reclassification for the models with and without 6 MWT. The addition of 6 MWT to the model resulted in an increase in Harrell's C statistic from 0.6897 to 0.7028 (p = .09), indicating a trend toward improvement of the model with the addition of the 6 MWT. Adding 6 MWT to the adjusted model resulted in an IDI of 4.4% and provided a category-free NRI of 28%. Of the 160 cardiovascular disease-related deaths among the 1,665 participants with a 6 MWT, coronary heart disease deaths accounted for more than half (100 [63%]), whereas the remaining deaths were due to strokes (39 [24%]), other atherosclerotic events (11 [7%]), and other cardiovascular events (10 [6%]).
The overall cardiovascular disease mortality rate was 12 per 1,000 personyears. A 6 MWT distance in the two shortest distance quintiles was associated Note. Presented as mean ±SD or n (%). Education = less than high school; BMI = body mass index; SBP = systolic blood pressure; ADL = activities of daily living; IADL = independent activities of daily living; CES-Depression = Center for Epidemiological Studies Depression Scale; MMSE = mini-mental status exam; ECG = electrocardiogram; AAI = ankle arm index; Chol = total cholesterol; Glucose = fasting glucose; C-RP = C-reactive protein; anti-HTN = anti-hypertensive medication.
with a twofold greater risk of cardiovascular disease deaths relative to those with a 6 MWT distance of >414 m in an unadjusted model. After adjusting for age and sex, the two shortest 6 MWT distance quintiles remained at increased risk for cardiovascular mortality. In fully adjusted model, the risk of cardiovascular mortality associated with the two shortest 6 MWT distance quintiles was no longer statistically significant (Table 2) . One hundred of the 504 deaths were attributed to coronary heart disease with an event rate of 8 per 1,000 person-years. A 6 MWT distance in the shortest distance quintile was associated with a 2.5-fold increased risk relative to those with a 6 MWT >414 m. After adjusting for age and sex, participants in the shortest 6 MWT distance quintile remained at increased risk for coronary heart disease mortality, but this association was no longer statistically significant in the fully adjusted model (Table 2 ).
MWT Distance and Incident Events
A total of 525 incident cardiovascular events and 305 incident coronary heart disease events occurred among the 1,665 participants with an overall incident rate of 36 per 1,000 person-years. Table 5 displays the association between 6 MWT distance and incident events. Participants who walked a distance of 290 m to 338 m and those with less than 290 m in the 6 MWT were at a 1.5-fold greater risk of incident cardiovascular events in the unadjusted model and also the model adjusted for age and sex. The inverse association between 6 MWT less than 290 m and incident cardiovascular disease was no longer significant in the fully adjusted model (HR = 1.2; 95% confidence interval [CI] = [0.8, 1.7]). Similarly, the observed association between those in the shortest 6 MWT distance quintile and incident coronary heart disease events in the unadjusted model (HR = 1.4; 95% CI = [1.0, 1.9]) was no longer statistically significant in the fully adjusted model (HR = 1.3; 95% CI = [0.8, 2.1]).
MWT Participants and Outcomes
Supplemental Tables 1 and 2 display the characteristics of participants with and without a 6 MWT and the association between 6 MWT and study endpoints, respectively. Participants with a 6 MWT were younger; were more likely to be men, to be of White race, and to have achieved a higher education level; less reported depressive symptoms; less often reported inability to perform ADLs or IADLs and higher cognitive function scores; and were less likely to have prevalent health conditions. Among the 4,708 participants who remained enrolled in CHS between 1996 and 1997, there were 2,286 deaths of which 556 were attributed to coronary heart disease. The overall mortality rate was 74.4 per 1,000 personyears. There was a significantly increased risk of death among participants without a 6 MWT (HR = 1.1; 95% CI = [1.0, 1.3]) and those without a clinic visit (HR = 1.8; 95% CI = [1.2, 2.7]). While a greater than twofold coronary heart disease mortality rate was observed among participants without a clinic visit relative to those with a 6 MWT during the clinic visit in unadjusted and age-and sex-adjusted models, this association was no longer significant in the fully adjusted model ( Supplemental Table 2 ). Similarly, the increased risk of incident events among participants without a 6 MWT was attenuated in a model adjusting for all other covariates.
Discussion
In a large cohort of community-dwelling older adults, we observed an independent inverse association between distance walked during a 6 MWT and mortality. Participants with a 6 MWT distance less than 338 m had more than a 1.5-fold greater risk of mortality relative to those who were able to walk 414 m or longer. Moreover, the 6 MWT provided additional information beyond various measures of psychosocial, physical, cognitive, and other comorbidities. However, the association between 6 MWT distance and coronary or cardiovascular-related outcomes was mostly explained by the overall poorer health status of the participants. Performance in walk-based testing has been shown to be correlated with cardiorespiratory fitness (Simonsick, Fan, Fleg, 2006) . Both self-reported walking ability and performance in distance-based walk tests have been shown to be predictors of disability, cardiovascular morbidity, and all-cause mortality (Guralnik et al., 1994; Newman et al., 2006; Vestergaard, Patel, Bandinelli, Ferrucci, & Guralnik, 2009) . Regarding the relationship between the 6 MWT distance and health outcomes, the inverse association with adverse outcomes has been previously demonstrated in disease-specific populations such as those with heart failure, pulmonary disease, and end-stage liver disease (Alahdab, Mansour, Napan, & Stamos, 2008; Boxer et al., 2010; Castel et al., 2009; Enfield et al., 2009; Carey et al., 2010) . However, the evidence on the association between 6 MWT and mortality in community-dwelling older adults has been limited. A study by Mutikainen et al. (2010) examined the association between 6 MWT performance and distance walked with all-cause mortality in a cohort of women aged 63 to 76 years. Older women who did not perform the 6 MWT were at a nearly sevenfold greater risk of mortality relative to women with a 6 MWT and who were able to walk ≥561 m. A similar increased mortality risk among those with no clinic and no 6 MWT was observed in our study of CHS participants, which is likely a result of poorer physical and cognitive health status. There was a non-statistically significant trend toward an increased risk of death with shorter distance walked when comparing participants with a 6 MWT distance ≤495 m relative to those with a distance ≥561 m (HR = 2.47; 95% CI = [0.81, 7.56]). Our study confirms the inverse association of both performance of the 6 MWT and distance walked with death in both men and women. In addition, our findings of the statistically significant association between distance walked on the 6 MWT and mortality extend on prior literature.
The conventional method for assessing functional capacity has been treadmill testing. Beyond detection of obstructive coronary disease, the treadmill test provides measure of an individual's functional capacity and predict of mortality (Blair et al., 1996; Goraya et al., 2000; Gulati et al., 2003; Kligfield & Lauer, 2006; Kokkinos et al., 2008; Messinger-Rapport et al., 2003; Mora et al., 2003; Myers et al., 2002; Spin et al., 2002; Sui et al., 2007) . Based on a cohort of 556 participants with stable coronary heart disease from the Heart and Soul Study, Beatty, Schiller, and Whooley (2012) reported a significant correlation (r = .66; p< .001) between 6 MWT distance and exercise capacity as measured by treadmill testing. In addition, the 6 MWT and treadmill testing had similar discrimination, integrated improvement, and NRI for prediction of cardiovascular endpoints.
Our study has several strengths and limitations. First, 6 MWT performance may not reflect a maximal effort similar to that obtained via treadmillbased exercise protocols. Second, approximately one third of participants with a clinic visit did not perform a 6 MWT. As shown in the supplementary analyses, 6 MWT participation status was associated with mortality. The strengths of our study include the large sample size of community-dwelling older adults, long follow-up time, extensive clinical examination, and standardized surveillance and ascertainment of hard outcomes.
Our study shows that both participation and distance walked on a 6 MWT are associated with mortality. A 6 MWT walk distance of 338 m appears to identify older aged men and women with poor prognosis. Moreover, the 6 MWT distance is of incremental prognostic value in community-dwelling older adults. Given the limited ability of older adults in completing treadmillbased protocols, the 6 MWT may provide a practical prognostic tool in older aged adults. Relative to treadmill testing, the 6 MWT has minimal associated equipment, safety, and cost issues. Our findings support the utility of the 6 MWT as a prognostic measure in community-dwelling older adults.
